期刊
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 92, 期 -, 页码 247-252出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2020.01.040
关键词
Klebsiella pneumoniae; Multidrug resistance; Carbapenemase; 16S rRNA methylase
资金
- International Health Cooperation Research [29-S-5]
- Japan Society for the Promotion of Science [18K07120]
- Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development [19fk0108061h0302]
Objectives: The aim of this study was to describe the emergence in Nepal of clinical isolates of Klebsiella pneumoniae harboring both bla(NDM-5) and bla(OXA-181/-232). Methods: Six clinical isolates of K. pneumoniae highly resistant to carbapenems and aminoglycosides were obtained from inpatients in Nepal. Their whole genomes were sequenced by a next generation sequencer. Results: The minimum inhibitory concentrations of meropenem, amikacin and ciprofloxacin were >= 128 mu g/ml, >1024 mu g/ml and >= 256 mu g/ml, respectively. All six isolates co-harbored bla(NDM-5), bla(OXA-181) or -232 and rmtB. Of them, 1 also harbored rmtF. The bla(NDM-5), bla(OXA-232) and rmtB in all six isolates were located on plasmids. Of the six isolates tested, one isolate harbored two copies of bla(OXA-181) and rmtF on the chromosome. Conclusions: This is the first report of clinical isolates of K. pneumoniae co-harboring bla(NDM-5), bla(OXA-181) or -232 and rmtB in Nepal. These strains were highly carbapenem-and aminoglycoside-resistant, and belonged to ST147 or ST395. Of them, ST147 isolate harbored two copies of bla(OXA-181) on the chromosome. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据